- Home
- ZCAR vs REVB Comparison
ZCAR vs REVB Comparison
Compare ZCAR & REVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZCAR
- REVB
- Stock Information
- Founded
- ZCAR 2013
- REVB 2020
- Country
- ZCAR India
- REVB United States
- Employees
- ZCAR N/A
- REVB N/A
- Industry
- ZCAR Blank Checks
- REVB Biotechnology: Pharmaceutical Preparations
- Sector
- ZCAR Finance
- REVB Health Care
- Exchange
- ZCAR Nasdaq
- REVB Nasdaq
- Market Cap
- ZCAR 2.9M
- REVB 2.8M
- IPO Year
- ZCAR N/A
- REVB N/A
- Fundamental
- Price
- ZCAR $3.88
- REVB $2.92
- Analyst Decision
- ZCAR
- REVB
- Analyst Count
- ZCAR 0
- REVB 0
- Target Price
- ZCAR N/A
- REVB N/A
- AVG Volume (30 Days)
- ZCAR 187.2K
- REVB 146.9K
- Earning Date
- ZCAR 02-14-2025
- REVB 05-09-2025
- Dividend Yield
- ZCAR N/A
- REVB N/A
- EPS Growth
- ZCAR N/A
- REVB N/A
- EPS
- ZCAR N/A
- REVB N/A
- Revenue
- ZCAR $9,117,419.00
- REVB N/A
- Revenue This Year
- ZCAR N/A
- REVB N/A
- Revenue Next Year
- ZCAR N/A
- REVB N/A
- P/E Ratio
- ZCAR N/A
- REVB N/A
- Revenue Growth
- ZCAR N/A
- REVB N/A
- 52 Week Low
- ZCAR $2.61
- REVB $2.36
- 52 Week High
- ZCAR $880.00
- REVB $60.80
- Technical
- Relative Strength Index (RSI)
- ZCAR 40.30
- REVB 45.77
- Support Level
- ZCAR $3.03
- REVB $2.76
- Resistance Level
- ZCAR $4.11
- REVB $3.62
- Average True Range (ATR)
- ZCAR 0.70
- REVB 0.41
- MACD
- ZCAR 0.48
- REVB 0.02
- Stochastic Oscillator
- ZCAR 67.20
- REVB 34.12
About ZCAR Zoomcar Holdings Inc.
Zoomcar Holdings Inc is India's largest marketplace for cars on rent. Zoomcar is a leading emerging-market-focused peer-to-peer car-sharing marketplace, with approximately 21,000 vehicles registered through its platform. The Company derives its revenue principally from short-term self-drive rentals and vehicle subscriptions. The self-drive rental business generates the majority of revenue. Geographically The company operates in India, Egypt, Indonesia, Vietnam, and the Philippines, Out of which the majority of revenue is derived from India.
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).